{"analyses":[{"ciLowerLimit":"1.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.83","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","paramType":"Odds Ratio (OR)","paramValue":"5.58","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"5.30","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"38.83","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"14.34","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"7.6","value":"3.1"},{"groupId":"OG001","lowerLimit":"11.1","upperLimit":"23.3","value":"16.3"},{"groupId":"OG002","lowerLimit":"25.7","upperLimit":"39.1","value":"32.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"184"}],"units":"Participants"}],"description":"PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 participants with baseline PRO measure for EB ≥ 2 and who had evaluable data for this outcome measure. A Non-responder Imputation (NRI) was applied for participants with missing data at the timepoint due to discontinuation or other intercurrent events.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}